News for XOMA Corporation (XOMAO)

Benchmark analyst Robert Wasserman has commenced coverage of Xoma Corporation (XOMA), assigning a Buy rating and setting a price target of $35. The analyst high

XOMA Royalty (XOMA) completes sale of five Kinnate pipeline assets for up to $270 million. The transaction includes upfront, milestone payments, and roy

We recently published a list of 20 Stocks Insiders Bought in April After Trump’s Tariff Rollout. In this article, we are going to take a look at where XOMA Royalty Corporation (NASDAQ:XOMA) stands against other stocks that insiders bought in April after Trump’s tariff rollout. President Donald Trump called April 2 a “Liberation Day” after […]

XOMA's preferred shares (XOMAO, XOMAP) offer secure, attractive yields backed by biotech royalties, FDA-approved assets, and strategic growth. See more here.

**media[583713]**

EMERYVILLE, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ( XOMA) today announced its Board of Directors has authorized the following ca

**media[568943]**

**media[531606]**

XOMA Royalty Corporation's portfolio includes riskier assets, impacting its stability. Find out why XOMA stock’s high-risk profile may not suit all investors.

Xoma Royalty's chief investment officer buys $13,974 in stock

**media[509408]**

XOMA Corporation (XOMA) experienced a significant stock movement, with its price rising by 5.45% to $32.70 per share. The trading volume reached 32,220 shares,

Genomics is the study of genes and how they function.

Twist Biosciences has a solid balance sheet but continues to face losses. Read why TWST stock may be hard to value despite its recent Q4 performance.

XOMA Royalty (XOMA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

XOMA Royalty (XOMA) delivered earnings and revenue surprises of 11.36% and 8.06%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Twist Bioscience executive sells shares worth $27,390

Twist Bioscience SVP sells $43,933 in stock

XOMA Corporation operates as a biotechnology royalty aggregator, acquiring economic rights to milestones and royalties from approved or clinical-stage drugs.